Storyboard

FDA to Probe How It Approved Biogen's Controversial Alzheimer's Drug

The head of the Food and Drug Administration is calling for an investigation into how her agency approved Biogen's Aduhelm, the first drug to treat Alzheimer's Disease in nearly two decades. This despite failing to receive an endorsement from an independent panel of experts, who said there was inconclusive evidence of the drug's efficacy. Recently, another panel ruled Aduhelm shows no benefit, and major U.S. hospitals and insurers have already declined to prescribe it.

FDA to Probe How It Approved Biogen's Controversial Alzheimer's Drug

Photo: ic-cdn.flipboard.com

Continue to read
13 stories in this Storyboard

Related articles

More stories from Medical Conditions

More stories from Alzheimer's Disease